Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMP4297 DDI Study with Itraconazole or Rifampicin in Healthy Subjects
NCT04584515Phase 1Completed
- Sponsor
- IMPACT Therapeutics
- Start
- Nov 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of senaparib in solid tumor (2 arms), sponsored by IMPACT Therapeutics. Primary endpoints: Maximum concentration at 3 months, Area under the curve from time 0 to last quantifiable concentration at 3 months and 1 more. Started Nov 2020; status: completed.
02
Drugs
senaparib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04584515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04584515.